Abstract
We have designed a highly sensitive assay based on the Safe-SeqS technology to detect de novo mutations in the KIT gene and tested its performance. This assay was applied to plasma samples of GIST patients before and after treatment with a multikinase inhibitor and mutations at known and novel sites of potential secondary resistance were identified.
Keywords
- ctDNA
- KIT
- Safe-SeqS
- Secondary resistance
- GIST
- NGS
This is a preview of subscription content, access via your institution.
Buying options



References
COSMIC (cancer.sanger.ac.uk), Forbes SA et al (2015) COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucl Acids Res 43(D1):D805–D811
Kinde I, Wu J, Papadopoulos N et al (2011) Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A 108(23):9530–9535
Author information
Authors and Affiliations
Corresponding authors
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this paper
Cite this paper
Fredebohm, J. et al. (2016). Detection and Quantification of KIT Mutations in ctDNA by Plasma Safe-SeqS. In: Gahan, P., Fleischhacker, M., Schmidt, B. (eds) Circulating Nucleic Acids in Serum and Plasma – CNAPS IX. Advances in Experimental Medicine and Biology, vol 924. Springer, Cham. https://doi.org/10.1007/978-3-319-42044-8_34
Download citation
DOI: https://doi.org/10.1007/978-3-319-42044-8_34
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-42042-4
Online ISBN: 978-3-319-42044-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)